Eli Lilly (LLY) Reports Positive Phase 3 Pediatric Data for EBGLYSS

Eli Lilly & Company (NYSE:LLY) is one of the best growth stocks to buy right now. On March 16, Eli Lilly announced positive topline results from the Phase 3 ADorable-1 trial, which evaluated EBGLYSS (lebrikizumab-lbkz) in pediatric patients as young as 6 months old with moderate-to-severe atopic dermatitis. As a selective IL-13 inhibitor, EBGLYSS met all primary and key secondary endpoints at Week 16.

Specifically, 63% of patients achieved a 75% reduction in skin inflammation, and 44% achieved clear or almost clear skin. These results are significant given that ~10 million children in the US are affected by this condition, many of whom lack adequate treatment options. The study also highlighted the drug’s impact on quality-of-life symptoms, with 35% of pediatric patients reporting significant relief from persistent itch. Mechanistically, EBGLYSS targets IL-13, a primary cytokine that drives the type-2 inflammatory cycle responsible for skin barrier dysfunction and thickening.

The trial utilized a weight-based dosing regimen, and the data showed that EBGLYSS provided a high bar of near-complete skin clearance in 39% of participants, nearly 4x the rate of the placebo group. The safety and tolerability profile remained consistent with previous studies in adults and adolescents. The most common adverse events included upper respiratory tract infections and nasopharyngitis, with no new safety signals or reports of injection site pain.

Eli Lilly & Company (NYSE:LLY) discovers, develops, and manufactures human pharmaceutical products. The company has collaborations with Boehringer Ingelheim Pharmaceuticals and F. Hoffmann-La Roche & Genentech, as well as license agreements with Almirall and Chugai Pharmaceutical.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.